Skip to content

BioCryst Pharmaceuticals

US · BCRX #2766 by market cap Listed 1970
8.40 +0.45 +5.66%
Live - 5344 symbols - heartbeat 108s ago · 2026-10-08 08:27
Pre-market 8.48 +0.91%
After-hours 8.38 -0.24%
Market cap
2.15B
P/B
-4.72
EPS
1.21
Reader sentiment Are you bullish or bearish on BCRX?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Needham Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $16
    Market Newswire · 2026/9/9
  • Rating change
    RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $13
    Market Newswire · 2026/8/6
  • Rating change
    BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $15
    Market Newswire · 2026/2/27
  • Rating change
    Wedbush Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $21
    Market Newswire · 2026/5/8
  • Rating change
    J.P. Morgan Downgrades BioCryst Pharmaceuticals(BCRX.US) to Hold Rating, Cuts Target Price to $12
    Market Newswire · 2026/7/13
  • Rating change
    J.P. Morgan Initiates a Hold Rating on BioCryst (BCRX)
    TipRanks · 2026/7/13
  • Rating change
    RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Raises Target Price to $14
    Market Newswire · 2026/7/7
  • Rating change
    Wedbush Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $21
    Market Newswire · 2026/7/13
  • Rating change
    Wedbush Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Raises Target Price to $22
    Market Newswire · 2026/3/2
  • Rating change
    A Quick Look at Today's Ratings for BioCryst Pharmaceuticals(BCRX.US), With a Forecast Between $13 to $30
    Market Newswire · 2026/2/27
  • Rating change
    A Quick Look at Today's Ratings for BioCryst Pharmaceuticals(BCRX.US), With a Forecast Between $16 to $32
    Market Newswire · 2026/7/1
  • Rating change
    BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating
    Market Newswire · 2026/4/16
  • Wedbush Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $20
    Market Newswire · 2026/8/6
  • Rating change
    TD Cowen Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/8/6
  • Rating change
    Wedbush Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $22
    Market Newswire · 2026/3/17
  • H.C. Wainwright Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $32
    Market Newswire · 2026/8/7
  • Rating change
    RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $13
    Market Newswire · 2026/3/25
  • Rating change
    BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Announces Target Price $15
    Market Newswire · 2026/7/15
  • J.P. Morgan Maintains BioCryst Pharmaceuticals(BCRX.US) With Hold Rating, Raises Target Price to $13
    Market Newswire · 2026/9/30
  • RBC Capital Downgrades BioCryst Pharmaceuticals(BCRX.US) to Hold Rating, Cuts Target Price to $11
    Market Newswire · 2026/9/10

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 08:27:26 · For reference only, not investment advice and not tailored to your situation.